Your session is about to expire
← Back to Search
Patritumab Deruxtecan for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new drug to see if it's effective and safe for patients with a certain type of lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My non-squamous NSCLC cannot be cured with surgery or radiation.My cancer worsened 12 months after initial treatment and progressed after third-gen EGFR treatment.My HIV infection is not well controlled.I am willing to undergo a tumor biopsy or provide recent tumor samples.I have a serious eye condition affecting my cornea.I haven't had any cancer except for certain skin cancers and treated cervical cancer in the last 3 years.I am taking more than 10 mg of prednisone or similar medication daily.My advanced lung cancer cannot be cured with surgery or radiation.I haven't had specific cancer treatments targeting topoisomerase I, HER3, or used certain systemic therapies in the advanced stage.My cancer progressed despite treatment with a specific lung cancer medication.My cancer has a specific EGFR mutation.I have an active hepatitis B or C infection.My cancer spread 12 months after initial treatment and worsened after a specific lung cancer therapy.I haven't had any treatments like chemotherapy or immunotherapy for my advanced cancer.My blood counts and organ functions are within the required ranges.I have severe breathing problems due to lung conditions or surgery.My cancer has a specific EGFR mutation.You have at least one visible and measurable abnormality according to the study guidelines.I've had 1 or 2 treatments with specific lung cancer drugs, including a newer type.I have untreated or symptomatic brain or spinal cord tumors needing medication.I haven't had any treatments like chemotherapy or immunotherapy for my advanced cancer.I am 18 years old or older.My cancer is confirmed as small cell, mixed small/non-small cell, or squamous non-small cell lung cancer.I have or might have a lung condition like ILD or pulmonary fibrosis.I have serious heart problems that are not under control.I have or had cancer spread to the lining of my brain and spinal cord.I am fully active or restricted in physically strenuous activity but can do light work.I am 18 years old or older.I've had 1 or 2 treatments with specific lung cancer drugs, including a newer type.
- Group 1: Platinum-based chemotherapy
- Group 2: Patritumab deruxtecan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does Patritumab Deruxtecan have any dangerous side effects for human patients?
"Patritumab Deruxtecan is a Phase 3 medication, so it has some evidence of efficacy and multiple rounds of safety data. Our team at Power gave it a score of 3 for safety."
How many total participants are needed for this research project?
"In order to start the clinical trial, 560 eligible participants are needed. These people must meet the specific inclusion criteria for the study and can come from locations like American Oncology Partners of Maryland in Bethesda or Innovative Clinical Research Institute in Whittier."
How many sites are running this clinical trial?
"There are 24 sites conducting this clinical trial, with locations in Bethesda, Whittier and Vallejo among others. If you enroll in the study, it is recommended that you choose a clinic nearest to your location to cut down on travel time."
Are investigators currently looking for new participants in this trial?
"Yes, the information on clinicaltrials.gov indicates that this trial is actively recruiting patients. The trial was first posted on May 10th, 2022 and was last updated on November 16th, 2022. The study is looking for 560 patients across 24 sites."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger